$CLLS News

Barclays Initiates Coverage On Cellectis with Overweight Rating, Announces Price Target of $9

Cellectis To Present Phase 1 CAR-T Data For Lasme-cel And Eti-cel At EHA 2026, Highlighting Early Safety, Response Signals And Ongoing Pivotal Programs

Cellectis Q1 Adj. EPS $(0.16) Beats $(0.27) Estimate, Sales $7.548M Miss $12.267M Estimate

Cellectis Presents New Research On TALE-Based Epigenetic Editing Approach At ASGCT Annual Meeting

Citizens Reiterates Market Outperform on Cellectis, Maintains $8 Price Target

European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading

European Equities Traded in the US as American Depositary Receipts Start Week Lower

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

Monthly information on share capital and company voting rights

European Penny Stocks To Watch: Market Caps Over €100M

Monthly information on share capital and company voting rights

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

Clear Street Initiates Coverage On Cellectis with Buy Rating, Announces Price Target of $9

Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday

Cellectis shares are trading lower after arbitration ruled in favor of Allogene in relation to cemacabtagene ansegedleucel.

Cellectis shares are trading lower after arbitration ruled in favor of Allogene in relation to cemacabtagene ansegedleucel.

Cellectis Announces Arbitral Decision in Dispute with Servier

Allogene Therapeutics Reports Result for Servier In Arbitration With Cellectis; Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel; Decision Reconfirms Allogene's Expanded Sub-License Covering EU And UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights

Cellectis' Allogeneic CAR-T Potential Still Justifies A 'Buy'